Anti-VEGFD 抗体 [EPR8457]

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFD antibody [EPR8457] (AB155288)

Immunohistochemical analysis of paraffin embedded Human skeletal muscle tissue using ab155288showing +ve staining.

• ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-VEGFD antibody [EPR8457] (AB155288)

ab155288 staining VEGFD in MCF-7 (human breast carcinoma) cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. Samples were incubated with primary antibody at a dilution of 1/200. A goat anti rabbit IgG (Alexa Fluor® 488) (ab150077) was used as the secondary antibody. ab7291 and ab150120 were used as counterstains for primary antibody ab155288 and secondary antibody ab150077 respectively and DAPI was used as a nuclear counterstain.

Negative control 1 : Rabbit primary antibody and anti-mouse secondary antibody (ab150120)
Negative control 2 : Mouse primary antibody (ab7291) and anti-rabbit secondary antibody (ab150077)

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFD antibody [EPR8457] (AB155288)

Immunohistochemical analysis of paraffin embedded Human normal kidney tissue using ab155288 showing +ve staining.

• IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFD antibody [EPR8457] (AB155288)

ab155288 staining VEGFD in human cardiac muscle tissue sections by Immunohistochemistry (IHC-P - Formalin/paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with paraformaldehyde and antigen retrieval was by heat mediation in a EDTA buffer. Samples were incubated with primary antibody at a dilution of 1/700. A goat anti-rabbit IgG H&L (HRP) ab97051 was used as the secondary antibody at a dilution of 1/500.

Negative control : PBS in place of primary antibody.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFD antibody [EPR8457] (AB155288)

Immunohistochemical analysis of paraffin embedded Human lung tissue labeling VEGFD with ab155288 at a 1/100 dilution.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFD antibody [EPR8457] (AB155288)

Immunohistochemical analysis of paraffin embedded Human heart tissue labeling VEGFD with ab155288 at a 1/100 dilution.

• Flow Cyt (Intra)

Lab

Flow Cytometry (Intracellular) - Anti-VEGFD antibody [EPR8457] (AB155288)

ab155288 staining VEGFD in the mouse cell line NIH/3T3 (mouse embryo) by intracellular flow cytometry.Cells were fixed with 4% paraformaldehyde and the sample was incubated with the primary antibody at a dilution of 1/200. A goat anti rabbit IgG (Alexa Fluor^® 488) at a dilution of 1/2000 was used as the secondary antibody.

Isoytype control : Rabbit monoclonal IgG (Black)

Unlabelled control : Cell without incubation with primary antibody and secondary antibody (Blue)

• WB

Lab

Western blot - Anti-VEGFD antibody [EPR8457] (AB155288)

Diluting and blocking buffer : 5% NFDM/TBST

All lanes:

Western blot - Anti-VEGFD antibody [EPR8457] (ab155288) at 1/10000 dilution

Lane 1:

Raji (human Burkitt's lymphoma) whole cell lysate at 20 µg

Lane 2:

HT1080 (human fibrosarcoma) whole cell lysate at 20 µg

Lane 3:

Caco-2 (human colorectal adenocarcinoma) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 40 kDa

Observed band size: 40 kDa

false

• WB

Unknown

Western blot - Anti-VEGFD antibody [EPR8457] (AB155288)

All lanes:

Western blot - Anti-VEGFD antibody [EPR8457] (ab155288) at 1/1000 dilution

Lane 1:

Raji lysate at 10 µg

Lane 2:

HT-1080 lysate at 10 µg

Lane 3:

MCF-7 lysate at 10 µg

Lane 4:

Caco-2 lysate at 10 µg

Predicted band size: 40 kDa

false

• WB

Lab

Western blot - Anti-VEGFD antibody [EPR8457] (AB155288)

Blocking/Diluting Buffer and concentration : 5% NFDM/TBST

All lanes:

Western blot - Anti-VEGFD antibody [EPR8457] (ab155288) at 1/10000 dilution

All lanes:

GST-Tagged human VEGFD (aa 1 to 354) recombinant protein

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/1000 dilution

Predicted band size: 40 kDa

Observed band size: 65 kDa

false

• WB

Lab

Western blot - Anti-VEGFD antibody [EPR8457] (AB155288)

Diluting and blocking buffer : 5% NFDM/TBST

All lanes:

Western blot - Anti-VEGFD antibody [EPR8457] (ab155288) at 1/2000 dilution

Lane 1:

Rat lung tissue lysate at 15 µg

Lane 2:

NIH/3T3 (mouse embryo) whole cell lysate at 15 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 40 kDa

Observed band size: 40 kDa

false

• WB

CiteAb

Western blot - Anti-VEGFD antibody [EPR8457] (AB155288)

VEGFD western blot using anti-VEGFD antibody [EPR8457] ab155288. Publication image and figure legend from Hong, H., Jiang, L., et al., 2016, BMC Cancer, PubMed 26992854.

ab155288 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab155288 please see the product overview.

TNF-α upregulated VEGF-D expression and VEGF-D promoter activity downstream of the ERK1/2/AP-1 pathway. a, c The effect of the TNF-α/AP-1 signaling pathway on the promoter activity and protein expression of the VEGF-D gene. Transfection with AP-1 siRNA effectively knocked down the expression of AP-1 and p-AP-1 in both NOZ and GBC-SD cells. The protein level and promoter activity of VEGF-D were accordingly reduced irrespective of treatment with TNF-α. b, d The effect of inhibition of MAPK pathway members on the protein expression and promoter activity of VEGF-D. When treated with SP600125 (10 μM), SB203580 (20 μM) or PD98059 (50 μM), the expression of AP-1 and p-AP-1 in both NOZ and GBC-SD cells were reduced. However, the protein expression and promoter activity of VEGF-D were significantly reduced only in the PD98059-treated group. *P < 0.05

false